Medpace
MEDP · Life Sciences Tools & Services
$669.20
2.3%Mettler Toledo
MTD · Life Sciences Tools & Services
$1,670.29
0.9%The short version
- Mettler Toledo is the larger business, with $4.0B of revenue in fiscal 2025 against $2.5B for Medpace, about 1.6 times as much.
- Medpace grew revenue faster (20.0%, against 4.0%).
- Medpace turned more of its sales into free cash flow (27.0% FCF margin, against 21.1% FCF margin).
- Investors pay more for each dollar of Mettler Toledo’s earnings: a P/E of 37.6x against 37.2x for Medpace.
| Latest fiscal year | MEDP · FY25 | MTD · FY25 |
|---|---|---|
| Size | ||
| Market cap | $19.0B | $33.7B |
| Revenue | $2.5B | $4.0B |
| Free cash flow | $682M | $849M |
| Net income | $451M | $869M |
| Growth | ||
| Revenue growth | 20.0% | 4.0% |
| 5-year growth | 22.3% | 5.5% |
| Share count change | −7.8% | −3.0% |
| Profitability | ||
| Gross margin | — | 59.4% |
| Operating margin | 21.1% | — |
| Net margin | 17.8% | 21.6% |
| FCF margin | 27.0% | 21.1% |
| Return on capital | — | 50.5% |
| Return on equity | 70.2% | — |
| Balance sheet | ||
| Net debt | −$497M | $2.0B |
| Net debt / EBITDA | −0.9x | 1.7x |
| Dividends and buybacks | $917M | $800M |
| Valuation & quality | ||
| P/E | 37.2x | 37.6x |
| Piotroski F-score | 4 | 7 |
FY16
MEDP $422M
MTD $2.5B
FY17
MEDP $436M
MTD $2.7B
FY18
MEDP $705M
MTD $2.9B
FY19
MEDP $861M
MTD $3.0B
FY20
MEDP $926M
MTD $3.1B
FY21
MEDP $1.1B
MTD $3.7B
FY22
MEDP $1.5B
MTD $3.9B
FY23
MEDP $1.9B
MTD $3.8B
FY24
MEDP $2.1B
MTD $3.9B
FY25
MEDP $2.5B
MTD $4.0B
MEDP
MTD
FY16
MEDP 12.5%
MTD —
FY17
MEDP 14.9%
MTD —
FY18
MEDP 14.3%
MTD —
FY19
MEDP 14.8%
MTD —
FY20
MEDP 18.0%
MTD —
FY21
MEDP 17.4%
MTD —
FY22
MEDP 19.1%
MTD —
FY23
MEDP 17.9%
MTD —
FY24
MEDP 21.2%
MTD —
FY25
MEDP 21.1%
MTD —
MEDP
MTD
FY16
MEDP $78.2M
MTD $337M
FY17
MEDP $85.7M
MTD $389M
FY18
MEDP $141M
MTD $422M
FY19
MEDP $184M
MTD $506M
FY20
MEDP $227M
MTD $632M
FY21
MEDP $235M
MTD $801M
FY22
MEDP $351M
MTD $738M
FY23
MEDP $397M
MTD $861M
FY24
MEDP $572M
MTD $864M
FY25
MEDP $682M
MTD $849M
MEDP
MTD
FY16
MEDP 4.2%
MTD 36.8%
FY17
MEDP 6.2%
MTD 31.7%
FY18
MEDP 11.6%
MTD 39.2%
FY19
MEDP 16.4%
MTD 41.6%
FY20
MEDP 25.7%
MTD 43.4%
FY21
MEDP 35.1%
MTD 51.4%
FY22
MEDP 53.7%
MTD 52.6%
FY23
MEDP 78.7%
MTD 48.6%
FY24
MEDP 161.7%
MTD 55.7%
FY25
MEDP —
MTD 50.5%
MEDP
MTD
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.